Nuclear Localization of Heme Oxygenase-1 in Pathophysiological Conditions: Does It Explain the Dual Role in Cancer?
Marilina Mascaró,
Eliana N. Alonso,
Exequiel G. Alonso,
Ezequiel Lacunza,
Alejandro C. Curino,
María Marta Facchinetti
Affiliations
Marilina Mascaró
Laboratorio de Biología del Cáncer, Instituto de Investigaciones Bioquímicas de Bahía Blanca (INIBIBB), Dpto. de Biología, Bioquímica y Farmacia (UNS), Universidad Nacional del Sur (UNS)-CONICET, Bahía Blanca 8000, Argentina
Eliana N. Alonso
Laboratorio de Biología del Cáncer, Instituto de Investigaciones Bioquímicas de Bahía Blanca (INIBIBB), Dpto. de Biología, Bioquímica y Farmacia (UNS), Universidad Nacional del Sur (UNS)-CONICET, Bahía Blanca 8000, Argentina
Exequiel G. Alonso
Laboratorio de Biología del Cáncer, Instituto de Investigaciones Bioquímicas de Bahía Blanca (INIBIBB), Dpto. de Biología, Bioquímica y Farmacia (UNS), Universidad Nacional del Sur (UNS)-CONICET, Bahía Blanca 8000, Argentina
Ezequiel Lacunza
Centro de Investigaciones Inmunológicas Básicas y Aplicadas (CINIBA), Facultad de Ciencias Médicas, Universidad Nacional de La Plata, La Plata CP1900, Argentina
Alejandro C. Curino
Laboratorio de Biología del Cáncer, Instituto de Investigaciones Bioquímicas de Bahía Blanca (INIBIBB), Dpto. de Biología, Bioquímica y Farmacia (UNS), Universidad Nacional del Sur (UNS)-CONICET, Bahía Blanca 8000, Argentina
María Marta Facchinetti
Laboratorio de Biología del Cáncer, Instituto de Investigaciones Bioquímicas de Bahía Blanca (INIBIBB), Dpto. de Biología, Bioquímica y Farmacia (UNS), Universidad Nacional del Sur (UNS)-CONICET, Bahía Blanca 8000, Argentina
Heme Oxygenase-1 (HO-1) is a type II detoxifying enzyme that catalyzes the rate-limiting step in heme degradation leading to the formation of equimolar quantities of carbon monoxide (CO), free iron and biliverdin. HO-1 was originally shown to localize at the smooth endoplasmic reticulum membrane (sER), although increasing evidence demonstrates that the protein translocates to other subcellular compartments including the nucleus. The nuclear translocation occurs after proteolytic cleavage by proteases including signal peptide peptidase and some cysteine proteases. In addition, nuclear translocation has been demonstrated to be involved in several cellular processes leading to cancer progression, including induction of resistance to therapy and enhanced metastatic activity. In this review, we focus on nuclear HO-1 implication in pathophysiological conditions with special emphasis on malignant processes. We provide a brief background on the current understanding of the mechanisms underlying how HO-1 leaves the sER membrane and migrates to the nucleus, the circumstances under which it does so and, maybe the most important and unknown aspect, what the function of HO-1 in the nucleus is.